Journal of ISSN: 2373-4426JPNC

Pediatrics & Neonatal Care
Volume 4 Issue 1 - 2016
Editorial: Retinopathy of Prematurity; A Synopsis
Mahmoud Elhalik1* and Khaled El-Atawi2
1Consultant Neonatologist, Head of Pediatric Department and Head of Health Informatics Unit, Latifa Hospital, UAE
2Consultant Neonatologist, NICU and Clinical Quality Specialist, Latifa Hospital, UAE
Received: January 17, 2016| Published: January 21, 2016
*Corresponding author: Khaled El-Atawi, Consultant Neonatologist, NICU and Clinical Quality Specialist, Latifa Hospital, DHA, Dubai, UAE, Email:
Citation: Elhalik M, El-Atawi K (2016) Editorial: Retinopathy of Prematurity; A Synopsis. J Pediatr Neonatal Care 4(1): 00124. DOI: 10.15406/jpnc.2016.04.00124


ROP: Retinopathy of Prematurity; ETROP: Retinopathy of Prematurity; VEGF: Vascular Endothelial Growth Factor; UCB: Umbilical Cord Blood
Retinopathy of prematurity (ROP) or retrolental fibroplasia is a vasoproliferative disorder that occurs to the retina of premature infants and was first diagnosed in 1942 by Terry [1]. ROP in severe cases damage the retina by detaching from the wall of the eye and possibly causing visual impairment and blindness [2, 3]. In the last 7 decades, there have been several advancements in the understanding and treatment of ROP. In spite of these advances, there are approximately 50,000-60,000 children globally who are blind as a result of ROP [4]. Every year in the U.S. about 14,000 get affected by ROP out of which about 1,100-1,500 develop advanced or severe diseases which require medical treatment and eventually 400-600 infants become blind [5]. In Middle East, over the last 10 years there is an increase observed in the ROP incidence from 23.1% to 56%. The burden of ROP is increasing rapidly and there is a need to focus on the earlier intervention and implementation of effective treatment strategies as this is a lifetime disease [6].
The major risk factors include prematurity, low birth weight, time of achievement of full feeding and hyperoxia. Other possible risk factors include anemia, blood transfusion, respiratory distress, and breathing difficulties. The underlying physiologic mechanism through which breast milk may protect against the development of ROP may reflect the antioxidant and immune protective properties of human milk [2,3,7,25].
ROP screening is generally done in babies whose birth weight is <1500 g or ≤32 weeks of gestation or selected infants by their neonatologist who are at higher risk. ROP is classified based on the location (zones I-III) and severity (stages I-V) as well as plus and pre-plus disease. Screening is required when ROP is severe i.e., from 3 to 18 weeks after birth depending on gestational age. Screening also depends on the decision of the management, which includes no further examination as the ROP is regressing, further examination is required after an interval of time or treatment is required immediately within 48 hours [4]. Consanguinity may also play a role in ROP development and further genetic studies may help in elucidating the pathogenesis [8]. In addition, Trisomy 21 significantly reduces ROP in very low birth weight infants. This can be developed into a laboratory-based ROP screening tool [9].


Experience in delivering the optimal care for ROP patients is required. The rate of treatment and re-treatment is inversely proportional to the experience of the ophthalmologist’s with and comfort in managing ROP [10].
The Early Treatment for Retinopathy of Prematurity (ETROP) study produced favorable results yielding new guidelines for treatment of infants with ROP. These included, early treatment of high-risk prethreshold ROP improves retinal and visual outcomes at 9 months corrected age and also indicated that early treatment can be avoided for certain eyes and be observed for signs of disease progression [11]. Katargina L study also showed that modern methods like optical coherence tomography and extraretinal growth parameters are an important criteria for the early diagnosis and helps in the detection of a preclinical negative trend in cicatricial ROP [12].
Treatment strategies for ROP include surgeries (like vitrectomy and scleral buckle), laser or cryotherapy etc. According to the CRYO-ROP trial, timely ablation (laser photocoagulation or retinal photoablation) of the avascular peripheral retina decreases the incidence by 40%. However, the failure rate of the therapy remained high. Hence frequent follow up and timely surgical intervention is warranted [13]. There is a correlation between the neovascular drive in ROP eyes with stage 3 disease and intraocular vascular endothelial growth factor (VEGF) levels that was successfully treated with intravitreal bevacizumab [14]. The BEAT-ROP trial presented the results that eyes with zone I threshold disease was better managed by bevacizumab than with conventional laser and zone II eyes was managed similarly by both the therapies. Most ROPs required single bevacizumab injection [15-17]. The outcomes of ROP treatment with bevacizumab after 2 years showed that 82% of infants have not had recurrence or any other complications that required intraocular surgery. Also early treatment with bevacizumab for cases of neovascularization can prevent bleeding and avoid surgical complication [18,19]. To control the VEGF levels that acts as a key factor in angiogenesis regulation in the developing retina as well as central nervous system, anti-VEGF drugs are used. Nevertheless, concerns remain due to their potential local and systemic adverse effects [20]. A powerful antioxidant and a VEGF inhibitor, D-penicillamine which when used to treat other disease that premature infants have, the treated infants had less ROP occurrence. However, no significant benefits of D-penicillamine was observed for the outcomes of ROP, death or development of nerves and hence not recommended [21]. Stem cell therapy with the help of umbilical cord blood (UCB) could present as an alternative treatment for ROP in preterm infants. To validate this, further in vivo studies are warranted [22].

Prevention of ROP [3,16,23-25]

i. Regulation of oxygen supply as both hypoxia and hyperoxia is detrimental to the baby so oxygen therapy should be carefully monitored by pulse oximetry. The saturation limit should be maintained between 90-95%.
ii. Permissive hypercapnia: reduced carbon dioxide is a risk factor for ROP. But this factor enables lower ventilator settings reducing the occurrence of lung diseases which requires prolonged oxygen use.
iii. Cautious use of blood transfusions: Adult RBCs are rich in 2,3-diphosphoglycerate and adult haemoglobin which binds less firmly to oxygen, thus releasing excess oxygen to the retinal tissue.
iv. Human milk feeding potentially plays a protective role in preventing any-stage ROP and severe ROP for very low birth weight infants.
v. Strict clinical and electronic monitoring which helps in early detection of disorders making a prompt treatment.
vi. Prenatal steroids help in preventing respiratory distress and intraventricular haemorrhage, which are the two important risk factors or ROP.
vii. Screening program with a proper neonatal unit, effective ROP surveillance and management decreases the severity of disease.


Risk factor analysis helps in understanding ROP development and can predict it in severe preterm infants. Hospitals should employ well-trained and experienced ophthalmologists for early ROP screening and treatment. Physicians should collaborate with neonatal intensive care unit coordinators for a good tracking system, which includes initial screenings to follow-up until post-discharge care. A high priority is given to the screening program conducted by the World Health Organization’s “Vision 2020 program”. These help in the institution of appropriate treatment to prevent blindness and offer child a better overall development.


  1. Terry TL (1942) Extreme prematurity and fibroblastic overgrowth of persistent vascular sheath behind each crystalline lens. I. Preliminary report. Am J Ophthalmol 25(2): 203-204.
  2. Roohipoor R, Riazi Esfahani M, Karkhaneh R, Ghassemi F, Ahmadabadi MN (2010) Anatomical outcome of 25-gauge vitrectomy associated with scleral buckling in stage 5 retinopathy of prematuriy: A case series study. Iranian Journal of Ophthalmology 22(2): 25-31.
  3. Stewart MW (2011) Current management of retinopathy of prematurity: The good, the bad and the ugly. J Clinic Experiment Ophthalmol 2(5): 1-2.
  4. Gilbert C, Wormald R, Fielder A, Deorari A, Zepeda-Romero LC, et al. (2015) Potential paradigm change in the detection of retinopathy of prematurity requiring treatment. Arch Dis Child Fetal Neonatal Ed 101(1): 6-9.
  5. National Eye Institute (2015) Facts about retinopathy of prematurity (ROP).
  6. Bin-Kathlan AA, Al-Ballaa FN, AlYahya AK (2014) Ophthalmic short- and long-term outcomes for premature infants: Results of an extended follow-up program in Saudi. Saudi Journal of ophthalmology 28(4): 268-273.
  7. Choi JY, Han YI, Kim JH, Kim ES, Jeon J (2014) The most important factors for retinopathy of prematurity in preterm infants. Korean J Perinatol 25(3): 153-158.
  8. Gharaibeh A, Khassawneh M, Khriesat W, Alkhatib S, Migdadi Y (2011) Adopting Western Retinopathy of Prematurity Screening Programs in Eastern Countries, are we Screening Properly? Middle East Afr J Ophthalmol 18(3): 209-213.
  9. Movsas TZ, Spitzer AR, Gewolb IH (2015) Trisomy 21 and risk of retinopathy of prematurity. Pediatrics 136(2): e441-e447.
  10. Kaakour AH, Hansen ED, Aziz HA, Young RC, Berrocal AM (2015) Changing treatment patterns for ROP at a tertiary medical center between 2002 and 2012. Ophthalmic Surg Lasers Imaging Retina 46(7): 752-754.
  11. Good WV (2004) Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. Trans Am Ophthalmol Soc 102: 233-248.
  12. Katargina L, Ryabtsev D (2014) ERG and OCT Changes In Cicatricial Retinopathy of Prematurity. Adv Ophthalmol Vis Syst 1(3): 1-6.
  13. Gadkari SS, Kulkarni SR, Kamdar RR, Deshpande M (2015) Successful surgical management of retinopathy of prematurity showing rapid progression despite extensive retinal photocoagulation. Middle East Afr J Ophthalmol 22(3): 393-395.
  14. Zhao M, Xie WK, Bai YJ, Huang LZ, Wang B, et al. (2015) Expression of total vascular endothelial growth factor and the anti-angiogenic VEGF165b isoform in the vitreous patients with retinopathy of prematurity 128(18): 2505-2509.
  15. Cryotherapy for Retinopathy of Prematurity Cooperative Group (1990) Multicenter trial of cryotherapy for retinopathy of prematurity. 3-month outcome. Arch Ophthalmol 108(2): 195-204.
  16. Mutlu FM, Sarici SU (2013) Treatment of retinopathy of prematurity: a review of conventional and promising new therapeutic options. Int J Ophthalmol 6(2): 228-236.
  17. Mintz-Hittner HA, Kennedy KA, Chuang AZ, BEAT-ROP Cooperative Group (2011) Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. N Engl J Med 364(7): 603-615.
  18. Mintz-Hittner HA (2013) Bevacizumab for retinopathy of prematurity: An update. Clinical Pharmacol Biopharmaceut 2(3): 18-20.
  19. Al-Aswad L (2007) Anti-VEGF drugs and neovascular glaucoma. Review of ophthalmology.
  20. Sankar MJ, Sankar J, Bhat V, Srinivasan R (2012) Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity(Protocol). The Cochrane review 3: 1-8.
  21. Qureshi MJ, Kumar M (2013) D-Penicillamine for preventing retinopathy of prematurity in preterm infants (review). Cochrane Database Syst Rev 9: 1-28.
  22. Lai AKW, Fu ZJ, Lo AC (2013) Stem Cell Therapy for Retinopathy of Prematurity. Anat Physiol 3:1-7.
  23. Enomoto S, Miki A, Matsumiya W, Honda S (2015) Evaluation of oxygen supplementation status as a risk factor associated with the development of severe retinopathy of prematurity. Ophthalmologica 234(3): 135-138.
  24. Manzoni P1, Stolfi I, Pedicino R, Vagnarelli F, Mosca F, et al. (2013) Human milk feeding prevents retinopathy of prematurity (ROP) in preterm VLBW neonates. Early Hum Dev 89(Suppl 1): S64-S68.
  25. Zhou J, Shukla VV, John D, Chen C (2015) Human Milk Feeding as a Protective Factor for Retinopathy of Prematurity: A Meta-analysis 136(6): e1576-e1586.
© 2014-2016 MedCrave Group, All rights reserved. No part of this content may be reproduced or transmitted in any form or by any means as per the standard guidelines of fair use.
Creative Commons License Open Access by MedCrave Group is licensed under a Creative Commons Attribution 4.0 International License.
Based on a work at
Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version | Opera |Privacy Policy